Loading stock data…
CDNA
$21.50+0.69 (+3.32%)
Market ClosedLast close May 1
CareDx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CareDx, Inc. in the Healthcare sector is trading at $21.50. The stock is currently near its 52-week high of $23.24, remaining 28.2% above its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why CDNA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$21.50
Potential Upside
5%
Whystock Fair Value$22.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$25.40+18.1%
Range$21.00 – $28.00
Fundamentals
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney tra...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.06B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.18%
Volume
Today's trading volume
834,131
Recent News
CareDx, Inc Q1 2026 Earnings Call Summary
Moby summary of CareDx, Inc's Q1 2026 earnings call
CareDx Inc (CDNA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
CareDx Inc (CDNA) reports a 39% revenue increase and raises 2026 guidance, while expanding into the oncology market with the acquisition of Naveris.
CareDx to Acquire Naveris to Expand Into Cancer MRD Testing
By Daniella Parra CareDx (Nasdaq: CDNA) said it signed a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for up to $260 million and will close in the third quarter. Naveris makes NavDx, a blood-based test that monitors patients with HPV-driven cancers after treatment, the company said. “Naveris has developed and commercialized […]
CareDx Q1 Earnings Call Highlights
CareDx (NASDAQ:CDNA) reported first-quarter 2026 results showing faster growth in its core testing and patient services businesses, while outlining two major portfolio moves: the pending divestiture of its lab products business and an agreement announced on the call date to acquire Naveris. Total r
CareDx (CDNA) Q1 2026 Earnings Call Transcript
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements are based upon current estimates and various assumptions.